Company news

Wave Life Sciences Ltd. news in 2022

Wave Life Sciences Ltd.'s news releases, calls and decks from 2022, newest first.

View company

Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy

December 18, 2022

Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets

December 12, 2022

Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update

November 9, 2022

Wave Life Sciences to Present at the Stifel 2022 Healthcare Conference

November 8, 2022

Wave Life Sciences to Webcast Conference Call of Third Quarter 2022 Financial Results on November 10, 2022

November 2, 2022

Wave Life Sciences to Highlight Advancements from PRISM Platform at Upcoming Scientific Congresses

October 2, 2022

Wave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic During Analyst and Investor Event

September 27, 2022

Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines Conference

September 26, 2022

Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington’s Disease

September 19, 2022

Wave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022

September 15, 2022

Wave Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update

August 10, 2022

Wave Life Sciences to Webcast Conference Call of Second Quarter 2022 Financial Results on August 11, 2022

July 27, 2022

Wave Life Sciences Announces Pricing of $70.0 Million Underwritten Offering

June 13, 2022

Wave Life Sciences to Present at the 2022 Jefferies Healthcare Conference

May 24, 2022

Wave Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update

May 11, 2022

Wave Life Sciences to Webcast Conference Call of First Quarter 2022 Financial Results on May 12, 2022

May 4, 2022

Wave Life Sciences Announces Publication of Foundational Preclinical Data Supporting Development of WVE-004 for C9orf72-associated ALS and FTD

April 24, 2022

Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

April 18, 2022

Wave Life Sciences Announces Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study Driven by Potent, Durable Reductions of Poly(GP) with Low, Single Doses of WVE-004

April 3, 2022

Wave Life Sciences to Present at Stifel 2022 CNS Days

March 20, 2022

Wave Life Sciences to Highlight RNA Base Editing Modality and Alpha-1 Antitrypsin Deficiency Program at Upcoming Scientific and Industry Meetings

March 14, 2022

Wave Life Sciences Announces Nature Biotechnology Publication Highlighting First RNA Base Editing in Non-Human Primates Using an Endogenous Enzyme

March 6, 2022

Wave Life Sciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

March 2, 2022

Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022

February 23, 2022

Wave Life Sciences to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference 2022

February 8, 2022

Wave Life Sciences Announces Two Papers in the Journal Nucleic Acids Research Describing How PN Backbone Chemistry Modifications Enhance the Pharmacological Effects of Oligonucleotides

February 1, 2022

Calls in 2022

Decks in 2022